LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

PTC Therapeutics Inc

Closed

SectorHealthcare

45.95 1.37

Overview

Share price change

24h

Current

Min

44.23

Max

46.17

Key metrics

By Trading Economics

Income

932M

867M

Sales

963M

1.2B

P/E

Sector Avg

7.068

56.602

EPS

10.04

Profit margin

73.681

Employees

939

EBITDA

3M

-47M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+38.12% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-158M

3.6B

Previous open

44.58

Previous close

45.95

News Sentiment

By Acuity

49%

51%

172 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

PTC Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

2 Dec 2024, 12:47 UTC

Major Market Movers

PTC Therapeutics Shares Jump on Pact With Novartis

Peer Comparison

Price change

PTC Therapeutics Inc Forecast

Price Target

By TipRanks

38.12% upside

12 Months Forecast

Average 62.58 USD  38.12%

High 113 USD

Low 40 USD

Based on 13 Wall Street analysts offering 12 month price targets forPTC Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

8

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

40.81 / 50.39Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

172 / 382 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.